Semaglutide reduces drinking in adults with alcohol use disorder and obesity
The Brown University Psychopharmacology Update · 2026-08 · 37 (8) · 1-6
DOI: 10.1002/pu.31472 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Brown University Psychopharmacology Update, online erschienen am 28.06.2026.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Weekly doses of semaglutide were more effective than placebo in reducing heavy drinking in patients with alcohol use disorder (AUD) and comorbid obesity, a 26‐week trial has found. Semaglutide also resulted in improvement in several metabolic measures, including weight and body mass index (BMI). Study results were published online May 2, 2026 in The Lancet .
Zitieren
APA
(2026). Semaglutide reduces drinking in adults with alcohol use disorder and obesity. The Brown University Psychopharmacology Update, 37(8), 1-6. https://doi.org/10.1002/pu.31472
Vancouver
Semaglutide reduces drinking in adults with alcohol use disorder and obesity. The Brown University Psychopharmacology Update. 2026;37(8):1-6. doi:10.1002/pu.31472
BibTeX
@article{euvimed2026,
title = {Semaglutide reduces drinking in adults with alcohol use disorder and obesity},
journal = {The Brown University Psychopharmacology Update},
year = {2026},
volume = {37},
number = {8},
pages = {1--6},
doi = {10.1002/pu.31472}
}
EUVIMED